Intuitive Surgical’s fourth quarter saw results above Wall Street’s expectations, driven by increased global procedure volumes and demand for the new da Vinci 5 system. Management highlighted continued adoption across multiple specialties, particularly in international markets, and noted that procedure growth was especially robust in Europe and Asia. CEO David Rosa pointed to the expansion of the da Vinci 5 in new geographies and indications as a key contributor, as well as growing use in ambulatory surgery centers (ASCs). While the company benefitted from broader system placements and higher recurring revenue, management also acknowledged ongoing pressures from tariffs and a more competitive landscape in China.
The National Health Service (NHS) in England has officially entered a new era of oncology with the launch of a revolutionary "ultra-early" lung cancer detection trial. Integrating advanced artificial intelligence with robotic-assisted surgery, the pilot program—headquartered at Guy’s and St Thomas’ NHS Foundation Trust as of January 2026—seeks to transform the diagnostic pathway from a [...]
NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while setting a bold trajectory for the year ahead. In its January 21, 2026, earnings call, the healthcare titan revealed it is
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released on January 21, 2026, the New Brunswick-based titan signaled a definitive pivot toward high-growth markets in oncology and cardiovascular technology. Despite
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts
Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of $2.53 per share was 11.6% above analysts’ consensus estimates.
Medical technology company Intuitive Surgical (NASDAQ:ISRG) announced better-than-expected revenue in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of $2.53 per share was 11.6% above analysts’ consensus estimates.
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the pharmaceutical industry’s most feared obstacle: the "patent cliff." Following a "catapult year" in 2025, the healthcare giant is projecting
